Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 476
Posts 80,630
Boards Moderated 23
Alias Born 09/05/02
160x600 placeholder
Heineken has agreed to sell its Mexican packaging business to Crown Holdings for $1.23 billion in cash, allowing the Dutch brewer to tighten its focus on beer.
More Top Equities Stories Of The Day
Apple Investigating Reports of iCloud Vulnerabilities
US Court Dismisses Aluminum Antitrust Cases
J.P. Morgan Working With Law Enforcement on Cyber Attack -- 3rd Update
U.S. Hot Stocks: Hot Stocks to Watch
Ex-LPL Broker Ordered to Pay Nearly $2 Million
U.S. Hot Stocks: Hot Stocks to Watch
Amazon, Twitter Gains Lead Techs Higher
Ukraine Tensions Spur U.S. Stock Futures Downward
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 181585 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist